AU2016289474C1 - HBED-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents - Google Patents
HBED-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents Download PDFInfo
- Publication number
- AU2016289474C1 AU2016289474C1 AU2016289474A AU2016289474A AU2016289474C1 AU 2016289474 C1 AU2016289474 C1 AU 2016289474C1 AU 2016289474 A AU2016289474 A AU 2016289474A AU 2016289474 A AU2016289474 A AU 2016289474A AU 2016289474 C1 AU2016289474 C1 AU 2016289474C1
- Authority
- AU
- Australia
- Prior art keywords
- group
- complex
- compound
- bone
- imaging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
- C07F9/3817—Acids containing the structure (RX)2P(=X)-alk-N...P (X = O, S, Se)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Radiology & Medical Imaging (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189652P | 2015-07-07 | 2015-07-07 | |
| US62/189,652 | 2015-07-07 | ||
| US201662320296P | 2016-04-08 | 2016-04-08 | |
| US62/320,296 | 2016-04-08 | ||
| PCT/US2016/041040 WO2017007790A1 (en) | 2015-07-07 | 2016-07-06 | Hbed-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2016289474A1 AU2016289474A1 (en) | 2018-02-01 |
| AU2016289474B2 AU2016289474B2 (en) | 2020-12-24 |
| AU2016289474C1 true AU2016289474C1 (en) | 2021-04-08 |
Family
ID=57685907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016289474A Active AU2016289474C1 (en) | 2015-07-07 | 2016-07-06 | HBED-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10253052B2 (enExample) |
| EP (1) | EP3319643B1 (enExample) |
| JP (1) | JP6792875B2 (enExample) |
| KR (1) | KR102651945B1 (enExample) |
| CN (1) | CN107847618B (enExample) |
| AU (1) | AU2016289474C1 (enExample) |
| CA (1) | CA2991498A1 (enExample) |
| DK (1) | DK3319643T3 (enExample) |
| EA (1) | EA201890221A1 (enExample) |
| IL (1) | IL256726A (enExample) |
| MX (1) | MX377208B (enExample) |
| WO (1) | WO2017007790A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX377208B (es) | 2015-07-07 | 2025-03-07 | Five Eleven Pharma Inc | Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos. |
| TW201832750A (zh) * | 2017-03-02 | 2018-09-16 | 美商５１１製藥公司 | 放射性藥品標記裝置 |
| WO2020028825A1 (en) * | 2018-08-03 | 2020-02-06 | Board Of Regents, The University Of Texas System | Method for extraction and purification of 68ga |
| CN109438517B (zh) * | 2018-12-27 | 2021-01-08 | 北京久杰净化工程技术有限公司 | 一种与羰基金属核心配位的双功能连接剂的配合物及其制备方法 |
| CA3137963A1 (en) * | 2019-04-26 | 2020-10-29 | Five Eleven Pharma Inc. | Prostate-specific membrane antigen (psma) inhibitors as diagnostic and radionuclide therapeutic agents |
| WO2021067513A1 (en) * | 2019-10-01 | 2021-04-08 | City Of Hope | Metal chelating agents and methods of using the same |
| DE102021101216A1 (de) * | 2021-01-21 | 2022-07-21 | Johannes Gutenberg-Universität Mainz, Körperschaft des öffentlichen Rechts | Markierungsvorläufer und Radiotracer zur nuklearmedizinischen Diagnose und Therapie von Prostatakrebs induzierten Knochenmetastasen |
| DE102022105175A1 (de) * | 2022-03-04 | 2023-09-07 | Atoms for Cure GmbH | Markierungsvorläufer und Radiotracer mit drei oder mehr Targeting-Vektoren für die nuklearmedizinische Theranostik |
| CN119060093B (zh) * | 2024-08-26 | 2025-09-05 | 广州医科大学附属第一医院（广州呼吸中心） | 一种靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法和应用 |
| CN119060094B (zh) * | 2024-08-26 | 2025-09-05 | 广州医科大学附属第一医院（广州呼吸中心） | 一种靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140038873A1 (en) * | 2011-04-13 | 2014-02-06 | Firmenich Sa | Equilibrated dynamic mixtures to control the release of perfuming aldehydes and ketones |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE329623T1 (de) * | 2001-10-22 | 2006-07-15 | Dow Global Technologies Inc | Radiopharmazeutishes mittel zur behandlung von krebs im frühstadium |
| EP1611119A1 (en) * | 2003-04-03 | 2006-01-04 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
| US7161000B2 (en) * | 2003-05-30 | 2007-01-09 | Sumitomo Chemical Company, Limited | Method for producing phenol condensate |
| US10925977B2 (en) * | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
| CN104774175B (zh) * | 2007-06-26 | 2019-04-16 | 约翰·霍普金斯大学 | 标记的前列腺特异性膜抗原(psma)的抑制子、生物学评估及作为成像试剂的用途 |
| JP5690733B2 (ja) * | 2009-08-20 | 2015-03-25 | 富士フイルムＲｉファーマ株式会社 | ビスホスホン酸誘導体及びその放射性金属核種標識体 |
| ITMI20121156A1 (it) | 2012-06-29 | 2013-12-30 | Consiglio Nazionale Ricerche | Metodo di elaborazione di immagini di tomografia a coerenza ottica |
| EP2862857A1 (en) * | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| MX377208B (es) | 2015-07-07 | 2025-03-07 | Five Eleven Pharma Inc | Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos. |
-
2016
- 2016-07-06 MX MX2018000239A patent/MX377208B/es active IP Right Grant
- 2016-07-06 EA EA201890221A patent/EA201890221A1/ru unknown
- 2016-07-06 CN CN201680046397.5A patent/CN107847618B/zh active Active
- 2016-07-06 AU AU2016289474A patent/AU2016289474C1/en active Active
- 2016-07-06 WO PCT/US2016/041040 patent/WO2017007790A1/en not_active Ceased
- 2016-07-06 CA CA2991498A patent/CA2991498A1/en active Pending
- 2016-07-06 JP JP2017568376A patent/JP6792875B2/ja active Active
- 2016-07-06 KR KR1020187002872A patent/KR102651945B1/ko active Active
- 2016-07-06 DK DK16821892.3T patent/DK3319643T3/da active
- 2016-07-06 EP EP16821892.3A patent/EP3319643B1/en active Active
- 2016-07-06 US US15/203,602 patent/US10253052B2/en active Active
-
2018
- 2018-01-03 IL IL256726A patent/IL256726A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140038873A1 (en) * | 2011-04-13 | 2014-02-06 | Firmenich Sa | Equilibrated dynamic mixtures to control the release of perfuming aldehydes and ketones |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018524352A (ja) | 2018-08-30 |
| KR20180026736A (ko) | 2018-03-13 |
| MX377208B (es) | 2025-03-07 |
| US20170022224A1 (en) | 2017-01-26 |
| WO2017007790A9 (en) | 2018-01-04 |
| DK3319643T3 (da) | 2020-06-15 |
| EP3319643A4 (en) | 2019-04-10 |
| CA2991498A1 (en) | 2017-01-12 |
| HK1254864A1 (en) | 2019-07-26 |
| EP3319643B1 (en) | 2020-04-22 |
| AU2016289474A1 (en) | 2018-02-01 |
| AU2016289474B2 (en) | 2020-12-24 |
| CN107847618A (zh) | 2018-03-27 |
| JP6792875B2 (ja) | 2020-12-02 |
| US10253052B2 (en) | 2019-04-09 |
| IL256726A (en) | 2018-03-29 |
| WO2017007790A1 (en) | 2017-01-12 |
| KR102651945B1 (ko) | 2024-03-26 |
| EP3319643A1 (en) | 2018-05-16 |
| EA201890221A1 (ru) | 2018-06-29 |
| CN107847618B (zh) | 2021-07-16 |
| MX2018000239A (es) | 2018-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016289474C1 (en) | HBED-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents | |
| AU2023203682B2 (en) | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy | |
| KR102870722B1 (ko) | 진단제 및 방사성핵종 치료제로서의 전립선-특이적 막 항원 (psma) 억제제 | |
| BR112020001785A2 (pt) | radiotraçador e compostos radioterapêuticos bimodais | |
| HK1254864B (en) | Hbed-bisphosphonates and radiometal conjugates thereof, useful as theranostic agents | |
| HK1248585B (zh) | Hbed-二膦酸盐/酯、其放射金属轭合物和它们作为治疗诊断剂的用途 | |
| HK1248585A1 (en) | Hbed-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents | |
| KR0153501B1 (ko) | 오르토 결합 작용기를 갖는 킬란트 및 그의 착물 | |
| HK1255215B (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 DEC 2020 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 22 DEC 2020 |
|
| FGA | Letters patent sealed or granted (standard patent) |